Category - Developments

Developments

Vital outlines plans for new Phase 3 ELAD trial

Vital Therapies (NASDAQ:VTL) has outlined plans for a possible new Phase 3 clinical trial designed to confirm ELAD’s safety and efficacy in alcohol-induced liver decompensation (AILD), including severe acute alcoholic...

September 28, 2015

Developments

Novadaq unveils SPY-Q Case Manager software

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has unveiled its SPY-Q Case Manager (SPY-QCM) software at the Symposium on Advanced Wound Care Fall 2015 meeting in Las Vegas. SPY-QCM is an image acquisition and analysis...

September 28, 2015

Developments

BioLight’s Eye-D to be featured at Boston conference

BioLight Life Sciences Investments’ (OTCQX:BLGTY; TASE:BOLT) Eye-D platform insert will be presented at the 5thAnnual Partnership Opportunities in Drug Delivery conference in Boston on Oct. 5. The Eye-D is BioLight’s...

September 24, 2015

Developments

Oramed gets patent for oral administration of proteins

The United States Patent and Trademark Office has approved Oramed Pharmaceuticals’ (NASDAQ: ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.” In a statement, CEO...

September 24, 2015

Developments

Dipexium presents Locilex data at ICAAC/ICC

Dipexium Pharmaceuticals and research collaborators, JMI Laboratories, have presented new Locilex microbiology data at the American Society for Microbiology’s Interscience Conference of Antimicrobial Agents and...

September 21, 2015

Developments

Braeburn Pharma commends HHS plan on opioid addition

Closely-held Braeburn Pharmaceuticals has commended U.S. Department of Health and Human Services (HHS) Secretary Sylvia Burwell on her announcement that HHS will expand access to medication-assisted treatment as part of...

September 18, 2015

Developments

Can-Fite gets FDA fast track for liver cancer drug

The FDA has granted Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, fast track designation asv a second line treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer...

September 17, 2015

Category - Developments

Vital outlines plans for new Phase 3 ELAD trial

Novadaq unveils SPY-Q Case Manager software

BioLight’s Eye-D to be featured at Boston conference

Oramed gets patent for oral administration of proteins

Dipexium presents Locilex data at ICAAC/ICC

Braeburn Pharma commends HHS plan on opioid addition

Can-Fite gets FDA fast track for liver cancer drug

General

More